Abstract
Despite the evidence that both type 1 and type 2 diabetes are presently treated with up-to-date therapeutic protocols, complete normalization of glycemic control for both diseases appears to be still out of reach. The gap existing between the “ideal” cure still to come and the present pharmacological treatment of diabetes is the cause of the development of microvascular diabetic complications such as nephropathy and retinopathy.
Keywords
- Diabetic Nephropathy
- Diabetic Retinopathy
- Diabetic Macular Edema
- Proliferative Diabetic Retinopathy
- Early Treatment Diabetic Retinopathy Study
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381–389
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 64:631–642
Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136
Martín-Merino E, Fortuny J, Rivero-Ferrer E, García-Rodríguez LA (2014) Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One 9(6):e100283
Scott I, Flynn H, Smiddy W (2010) Diabetes and ocular disease: past, present, and future therapies, 2nd edn. American Academy of Ophthalmology Monograph:14. Oxford University Press
Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682
Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227–1239
Campochiaro PA (2013) Ocular neovascularization. J Mol Med (Berl) 91:311–321
Shah CP, Chen C (2011) Review of therapeutic advances in diabetic retinopathy. Ther Adv Endocrinol Metab 2:39–53
Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd (2009) Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 127:132–140
Tremolada G, Del Turco C, Lattanzio R, Maestroni S, Maestroni A, Bandello F, Zerbini G (2012) The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment. Exp Diabetes Res 2012:728325
Arden GB, Sivaprasad S (2012) The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol 124:15–26
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967
Prater DN, Case J, Ingram DA, Yoder MC (2007) Working hypothesis to redefine endothelial progenitor cells. Leukemia 21:1141–1149
Zerbini G, Lorenzi M, Palini A (2008) Tumor angiogenesis. N Engl J Med 359:763
Medina RJ, O’Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA (2010) Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 3:18
Lois N, McCarter RV, O’Neill C, Medina RJ, Stitt AW (2014) Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne) 5:44
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593–600
Tan K, Lessieur E, Cutler A, Nerone P, Vasanji A, Asosingh K, Erzurum S, Anand-Apte B (2010) Impaired function of circulating CD34(+) CD45(−) cells in patients with proliferative diabetic retinopathy. Exp Eye Res 91:229–237
Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW (2002) Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 8:607–612
Zerbini G, Maestroni A, Palini A, Tremolada G, Lattanzio R, Maestroni S, Pastore MR, Secchi A, Bonfanti R, Gerhardinger C, Lorenzi M (2012) Endothelial progenitor cells carrying monocyte markers are selectively abnormal in type 1 diabetic patients with early retinopathy. Diabetes 61:908–914
Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type I (insulin-dependent) diabetes mellitus. Diabetologia 28:290–296
Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496–501
Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L (2014) Changes in diabetes-related complications in the United States, Oxford University Press, New York, New York, USA 1990–2010. N Engl J Med 370:1514–1523
Seaqvist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161–1165
Viberti GC, Keen H, Wiseman MJ (1987) Raised arterial pressure in parents of proteinuric insulin dependent diabetics. Br Med J 295:515–517
Rudberg S, Stattin EL, Dahlquist G (1998) Familial and perinatal risk factors for micro- and macroalbuminuria in young IDDM patients. Diabetes 47:1121–1126
Krolewski AS, Canessa M, Warram JH, Laffel LMB, Christlieb AR, Knowler WC, Rand LI (1988) Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318:140–145
Mangili R, Bending JJ, Scott G, Li LK, Gupta A, Viberti GC (1988) Increased sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy. N Engl J Med 318:146–150
Canessa M, Adragna N, Solomon HS, Connolly TM, Tosteson DC (1980) Increased sodium-lithium countertransport in red cells of patients with essential hypertension. N Engl J Med 302:772–776
Zerbini G, Ceolotto G, Gaboury C, Mos L, Pessina AC, Canessa M, Semplicini A (1995) Sodium-lithium countertransport has low affinity for sodium in hyperinsulinemic hypertensive subjects. Hypertension 25:986–993
Williams RR, Hunt SC, Kuida H, Smith JB, Ash KO (1983) Sodium-lithium countertransport in erythrocytes of hypertension prone families in Utah. Am J Epidemiol 118:338–344
Hasstedt SJ, Wu LL, Ash KO, Kuida H, Williams RR (1988) Hypertension and sodium-lithium countertransport in Utah pedigrees: evidence for major locus inheritance. Am J Hum Genet 43:14–22
Hunt SC, Stephenson SH, Hopkins PN, Hasstedt SJ, Williams RR (1991) A prospective study of sodium-lithium countertransport and hypertension in Utah. Hypertension 17:1–7
Laurenzi M, Cirillo M, Panarelli W, Trevisan M, Stamler R, Dyer AR, Stamler J (1997) Baseline sodium-lithium countertransport and 6-year incidence of hypertension. The Gubbio population study. Circulation 95:581–587
Monciotti CG, Semplicini A, Morocutti A, Maioli M, Cipollina MR, Barzon I, Palaro C, Brocco E, Trevisan M, Fioretto P, Crepaldi G, Nosadini R (1997) Elevated sodium-lithium countertransport activity in erythrocytes is predictive of the development of microalbuminuria in IDDM. Diabetologia 40:654–661
Zerbini G, Maestroni A, Breviario D, Mangili R, Casari G (2003) Alternative splicing of NHE-1 mediates Na-Li countertransport and associates with activity rate. Diabetes 52:1511–1518
Fioretto P, Steffes MW, Brown DM, Mauer SM (1992) An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 20:549–558
Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69–75
Luzi L (1998) Pancreas transplantation and diabetic complications. N Engl J Med 339:115–117
The Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703–1720
Steiner DF, Cunningham D, Spigelman L, Aten B (1967) Insulin biosynthesis: evidence for a precursor. Science 157:697–700
Rubenstein AH, Cho S, Steiner DF (1968) Evidence for proinsulin in human urine and serum. Lancet 1:1353–1355
Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson BL, Rigler R, Jörnvall H (2000) Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278:E759–E768
Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren P, Stâhl S, Ekberg K, Johansson B, Uhlén S, Uhlén M, Jörnvall H, Wahren J (1999) Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 96:13318–13323
Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563–566
Sjöquist M, Huang W, Johansson BL (1998) Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 54:758–764
Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 17:181–189
Zerbini G, Mangili R, Luzi L (1999) Higher post-absorptive C-peptide levels in Type 1 diabetic patients without renal complications. Diabet Med 16:1048
Forst T, De La Tour DD, Kunt T, Pfützner A, Goitom K, Pohlmann T, Schneider S, Johansson BL, Wahren J, Löbig M, Engelbach M, Beyer J, Vague P (2000) Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K + −ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 98:283–290
Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group (2014) Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 63:739–748
Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M (2007) Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56:2155–2160
Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG (2012) Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82:1010–1017
Pavenstädt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83:253–307
Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, Liu BC (2011) Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 6:e20431
Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J (2005) Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16:1733–1741
Vogelmann SU, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285:F40–F48
Mundel P (2003) Urinary podocytes: lost and found alive. Kidney Int 64:1529–1530
Sakairi T, Abe Y, Kajiyama H, Bartlett LD, Howard LV, Jat PS, Kopp JB (2010) Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol 298:F557–F567
Jopling C, Boue S, Izpisua Belmonte JC (2011) Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol 12:79–89
Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV (2013) The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304:F333–F347
Maestroni S, Maestroni A, Dell’Antonio G, Gabellini D, Terzi S, Spinello A, Meregalli G, Castoldi G, Zerbini G (2014) Viable podocyturia in healthy individuals: implications for podocytopathies. Am J Kidney Dis 64:1003–1005
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Zerbini, G., Maestroni, S. (2017). Long-Term Microvascular Complications: New Ideas for Research. In: Scaramuzza, A., de Beaufort, C., Hanas, R. (eds) Research into Childhood-Onset Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-319-40242-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-40242-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40240-6
Online ISBN: 978-3-319-40242-0
eBook Packages: MedicineMedicine (R0)